Pharmabiz11h
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...
Pharmabiz2d
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
Business Wire14d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...
Finanznachrichten1d
AstraZeneca PLC: Dato-DXd new BLA submitted, NSQ BLA withdrawn
Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor ...
Morningstar14d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
Datopotamab deruxtecan is a specifically engineered ... attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.
London South East23d
Avacta Group Share Chat (AVCT)
The market leading antibody-drug conjugate, Enhertu (co-owned by Daiichi Sankyo and AstraZeneca), uses a derivative of exatecan (deruxtecan) as its warhead. Note that the consensus forecast is for ...
Nature22d
Billion-dollar bets on antibody–drug conjugates
For example, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan ... the hydrophobicity of the topoisomerase 1 inhibitor exatecan, enabling a high drug–antibody ratio (DAR ...
The Globe and Mail8d
HR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with ...
Cancer Research7d
First Disclosures
Is Efficacious in Human Ovarian and Kidney Cancer Models DXd ADC is a novel ADC therapeutic designed with a potent DNA topoisomerase I inhibitor exatecan delivative. Raludotatug deruxtecan (R-DXd) is ...